

ANDREW M. SHAPIRO, M.D.

Chesapeake Urology Associates, P.A.
The Continence Center
21 Crossroads Drive, Suite 450
Owings Mills, MD 21117
410-581-8140 - Office
410-356-0885 - Fax

Chesapeake Urology Associates, P.A.
826 Washington Road, Suite 215
Westminster, MD 21157
410-876-1633 - Office
410-871-1074 - Fax

EDUCATION:

May 1994	University of Pennsylvania Philadelphia, Pennsylvania B.S.
May 2000	University of Pittsburgh School of Medicine Pittsburgh, Pennsylvania M.D.

INTERNSHIP:

June 2000-2001	University of Texas Health Science Center at Houston Houston, Texas Intern - General Surgery
----------------	--

RESIDENCY TRAINING:

July 2001-June 2005	University of Texas Health Science Center at Houston Houston, Texas Resident - Urologic Surgery
---------------------	---

FELLOWSHIP:

June 2005-June 2006	University of Texas Health Science Center at Houston Houston, Texas Fellow in Female Urology, Neurology and Urinary Tract Reconstruction
---------------------	---

WORK HISTORY:

2006-Present Chesapeake Urology Associates Center for Continence
Owings Mills, Maryland
Staff Physician

2007-Present Summit Clinical Research Associates
Owings Mills, Maryland
Sub-Investigator

SCIENTIFIC PRESENTATIONS:

Shapiro, A, Ahrar K, Wood CG, Pisters LL, Matin SF, Preliminary Results of Percutaneous Radio Frequency Ablation for Locally Recurrent of Metastatic Renal Cell Carcinoma, Southwest Section of the American Urologic Association, Podium, Boston 2003.

Shapiro, A, Kamat, A. Diffuse Granulomatous Disease caused by Intravesical Bacillus Calmette-Guerin (BCG) Installation Masquerading as Peritoneal Carcinomatosis, Southwest Section of the American Urological Association, T Leon Howard Pyelogram, Ireland 2004.

CLINICAL RESEARCH EXPERIENCE:

Sub-Investigator

A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of Fesoterodine as an "Add-On" Therapy in Men with Persistent Overactive Bladder Symptoms Under Monotherapy of Alpha Blocker for Lower Urinary Tract Symptoms.

Sub-Investigator

A Phase II, 16 Week, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Proof of Concept Study Evaluating the Efficacy and Safety of PF-04383119 for the Treatment of Pain Associated with Interstitial Cystitis.

Sub-Investigator

A 12 Week, Randomized, Double-Blind, Placebo- Controlled, Parallel-Group, Multicenter Trial to Evaluate the Efficacy and Safety of a Fesoterodine Flexible Dose Regimen in Patients with Overactive Bladder.